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Abstract 
Bovine anaplasmosis is a tick-borne bacterial disease caused by Anaplasma marginale, a global 
pathogen estimated to cost the U.S. cattle industry >$300 million per year. Anaplasmosis 
treatment and control strategies rely heavily on tetracycline antibiotics; however, variations in 
susceptibility to this antibiotic class among A. marginale strains have been documented. Use of 
characterized contemporary strains is important when evaluating or re-evaluating antimicrobial 
management strategies. The first objective of our work was to locate and propagate two isolates 
of A. marginale actively circulating in Kansas cattle herds and characterize the progression of 
infection and clinical disease associated with these contemporary isolates in adult beef cattle. 
Adult beef cows naturally infected with contemporary A. marginale strains not previously 
isolated or studied were identified from the Kansas State University Cow-Calf herd, a herd 
naturally endemic for anaplasmosis. Blood samples containing these uncharacterized A. 
marginale isolates (KS1 and KS2) were collected and sub-inoculated into splenectomized calves 
for isolate propagation. To characterize the virulence and infection kinetics of these isolates, 
adult beef cows were inoculated with stabilates of A. marginale isolates ‘KS1’ and ‘KS2’, and 
clinical disease and isolate infection kinetics were monitored using packed cell volume and 
polymerase chain reaction assays, respectively. Animals challenged with KS1 reached clinical 
anaplasmosis by 35 days  post-inoculation (dpi), approximately 3 days earlier than KS2-
challenged animals. Animals challenged with KS1 reached a peak bacteremia of 3.43×106 
bacteria/mL blood, whereas KS2-challenged animals reached 9.46×108 bacteria/mL blood. Both 
isolates caused clinical anasplasmosis in challenged animals that required treatment intervention; 
however, KS1 and KS2 had distinict infection kinetic characteristics. These isolates will be used 
in future studies to evaluate or re-evaluate the efficacy of antimicrobial-based anaplasmosis 
  
treatment and control strategies. Collectively, the work presented in this thesis will contribute to 
the need for data-driven recommendations for effective and judicious antimicrobial-based 
anaplasmsosis management strategies.   
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Glossary 
***Terms are defined in reference to Anaplasma marginale or anaplasmosis. 
Acute phase: phase of disease when clinical anaplasmosis symptoms are typically experienced 
and greatest levels of A. marginale infection levels are observed. 
Antimicrobial susceptibility: susceptibility of a bacteria to antibiotics. 
Bacteremia: quantification of bacteria in the blood. 
Biological transmission: mode of transmission in which pathogen replication occurs; most 
effective and efficient mode of transmission. 
Contemporary strains: actively circulating A. marginale field strains that have been exposed to 
natural and management-driven selection pressures. 
Endemic: an area where a disease/pathogen is regularly identified. 
Genotype: for A. marginale, the sequential arrangement of individual tandem repeats in the 
Msp1a gene. 
Historical strains: strains of A. marginale isolated and characterized decades ago that have not 
been exposed to the same intensity and frequency of selection pressures as contemporary 
strains.  
Infection kinetics: changes in A. marginale bacterial levels in cattle during the course of 
infection. 
Inoculation: act of introducing the infective pathogen into the host. 
Isolate: refers to the source of A. marginale, which may contain multiple A. marginale 
strains/genotypes. 
Mechanical transmission: mode of transmission in which no pathogen replication occurs; 
movement of infected material from an infected host to a naïve host; less efficient. 
xii 
PCV nadir: the lowest observed packed cell volume record for an animal. 
Persistent phase: phase of disease characterized by cyclical fluctuations of A. marginale 
bacteremia during which signs of clinical disease are rarely observed. 
Phenotype: observable characteristics of an individual A. marginale isolate or strain. 
Propagation: method of replicating A. marginale isolates or strains, usually in an 
immunocompromised animal. 
Seroprevalence: percentage of animals with pathogen-specific antibodies. 
Splenectomized: an animal that has had its spleen removed; a procedure performed to 
culture/grow high levels of A. marginale. 
Stabilate: infectious material produced from propagation of A. marginale that is commonly used 
as the inoculum in experimental animal infections. 
Strain: in this study, defined by the A. marginale Msp1a genotype. 
Vector: an object or tick that transmits the pathogen from one animal to another. 
Virulence: the severity of disease. 
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Chapter 1 - Review of Literature 
 Overview of Anaplasmosis 
Bovine anaplasmosis, caused by the obligate intracellular rickettsial pathogen Anaplasma 
marginale, is an economically important hemolytic disease of domesticated cattle. First 
discovered by Smith and Kilbourne in 1893, A. marginale was mistakenly thought to be part of 
the life cycle of the protozoal pathogen Babesia bigemina (Smith and Kilbourne, 1893). In the 
early 1900’s, Sir Arnold Theiler was able to differentiate between babesiosis and anaplasmosis. 
Animals that were previously inoculated with South African redwater (Babesia bigemina) later 
developed disease when injected with blood from animals infected with the then unknown A. 
marginale. Sir Arnold Theiler concluded that due to its longer incubation period, its prolonged 
duration, and the observation of coccus-like marginal points, this disease was different from 
babesiosis. Theiler coined the name “anaplasma” and initially believed this to be a protozoan 
pathogen (Theiler, 1911). As Theiler conducted experiments on this disease, he found the 
pathogen located in marginal points within red blood cells in some 
animals and located more central points within red blood cells in 
others. Theiler also noticed that the distinct configurations 
displayed unique disease properties. To distinguish between the two 
“anaplasms”, he designated one Anaplasma marginale (Figure 1.1), 
and the other Anaplasma marginale (variety centrale).  
All ages of cattle are susceptible to A. marginale, but mature 
animals develop more severe disease. The following list of clinical 
symptoms of anaplasmosis was part of an in-depth review by Jones 
and Brock (1966). The first recorded sign of disease was an 
Figure 1.1 – Anaplasma 
marginale (basophilic-
staining bodies) infected 
bovine erythrocytes 
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increased temperature. The successive clinical symptoms resulted from the onset of anemia, a 
condition in which there are not enough healthy red blood cells to adequately supply body tissues 
with oxygen. When the red blood cell count (hematocrit) was decreased by 40 to 50% (Figure 
1.2), clinical signs were more consistently recognized, and animals displayed lethargy, 
depression, weight loss, decreased milk production, pale mucous membranes (Figure 1.2), and 
thin watery blood. Some animals became restless and excited when forced to move, as cardiac 
rate and output increased, and cerebral anoxia set in. Abortion was also observed due to infection 
during advanced stages of pregnancy, as well as temporary infertility in breeding bulls. Icterus 
(Figure 1.2) was seen during the early stages of convalescence but those that did not convalesce 
died from complications associated with severe anemia. The animals that survived acute disease 
became persistently infected and served as transmission reservoirs for the pathogen (Jones and 
Brock, 1966). 
 
The role and mechanics of persistent A. marginale infection in host animals was largely 
unknown until 1989 when Eriks et al. developed a nucleic-acid probe that was more sensitive to 
Figure 1.2 – Clinical symptoms of anaplasmosis. Hematocrit of animal suffering severe anemia 
(left), pale mucous membranes from onset of anemia (center), icteric vulva (Hashem et al., 2018) 
(right). 
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detecting low levels of parasitemia in carrier cattle. Using this hybridization assay, they observed 
highly variable parasitemia levels among carrier cattle ranging from greater than 0.0025 to less 
than 0.000025% infected erythrocytes. The observed range of parasitemia levels implied that a 
smaller percentage of infected erythrocytes was associated with lesser risk of pathogen 
transmission (Eriks et al., 1989). Kieser et al. (1990) further characterized persistent A. 
marginale infection and demonstrated a logarithmic variation of bacteremia in persistently 
infected cattle. They noted that the cyclical fluctuation (Figure 1.3) from less than 103 to greater 
than 105 infected erythrocytes/mL of whole blood could be consistent with the development of 
antigenic variations that the host’s immune system did not recognize (Kieser et al., 1990).  
The fact that the immune system was capable of preventing development of high parasitemia 
levels observed during acute infection but was incapable of clearing a low-level persistent 
infection suggested a mechanism of escape from the immune response (Palmer et al., 2000). One 
such method of escape by A. marginale was found to be related to natural antigenic variation 
among two immunogenic surface proteins: major surface protein 2 (Msp2) and major surface 
protein 3 (Msp3). It was found that before complete clearance of variants by the immune system, 
new variants emerged that were not recognized by the immune response (Palmer et al., 2000). 
The new Msp2 escape variants were expressed in each new bacteremic cycle, which were about 
six weeks in durations. Using this rate of variant expression over a 7-year period, greater than 
240 different variants would have potentially challenged the host’s immune system. Each cycle 
during persistent infection resulted in an increased level of parasitemia that quickly decreased, 
likely due to the immune response recognizing most, but not all, of the Msp2 variants expressed 
(French et al., 1998). The increased level of parasitemia reached during each cycle of persistent 
infection was lower than that reached during initial infection and rarely resulted in clinical 
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manifestations (Figure 1.3). In contrast, if an animal became immunosuppressed and unable 
immunologically to counter the emergence of a new variant, that animal developed recrudescent 
clinical anaplasmosis. 
 
Multiple diagnostic tests have been developed to diagnose A. marginale infection or 
exposure. For the purposes of this thesis, the three diagnostic tests used in our lab (i.e., light 
microscopy, cELISA, and PCR) will be reviewed. Light microscopy of stained blood smears was 
the first diagnostic test used to identify and diagnose A. marginale infection of bovine 
erythrocytes (Smith and Kilbourne, 1893; Theiler, 1911). This diagnostic method was most 
useful during acute clinical disease when the bacteremia was greater than 1×107 A. 
marginale/mL of blood. At lesser bacteremia levels, including during persistent infection in 
carrier animals, blood smear observation of infection is often not practical or possible. 
Consequently, this diagnostic method was most effective when animals were suffering clinical 
symptoms, as a result of the onset of anemia. In severely anemic animals, this diagnostic method 
Figure 1.3 – Infection cycle of A. marginale.  Increased bacteremia during acute infection 
followed by cyclical fluctuations reaching bacteremia levels lower than initial infection through 
persistent infection (Kocan et al., 2003). 
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may also be of limited utility due to spleen-removal of most of the infected erythrocytes from the 
bloodstream (Potgieter and Stoltsz, 1994).  
A competitive inhibition enzyme-linked immunosorbent assay (cELISA) was developed 
in 1996 by Knowles et al. to determine the presence of bovine antibodies against Anaplasma 
major surface protein 5 (Msp5). Detection of these antibodies indicated that the animal being 
sampled was exposed to and possibly infected with A. marginale. This assay utilized a 
monoclonal antibody (Mab) ANAF16C1 that recognized Msp5 among Anaplasma spp (Knowles 
et al., 1996). This diagnostic assay is the most practical means of evaluating large groups of 
animals due to price, speed, and limited diversity among Anaplasma spp infecting cattle in the 
United States. As animals commonly become persistently infected with A. marginale, animals 
with a positive serologic test result are often interpreted as actively infected with A. marginale.  
A third diagnostic method, quantitative polymerase chain reaction (qPCR), detects the 
pathogen itself (specifically pathogen genetic material ), including trace amounts of pathogen in 
carrier animals. By amplifying certain fragments of A. marginale-specific nucleic acid, qPCR 
assays can detect as little as 10 A. marginale bacteria/mL of blood. A recently developed assay 
demonstrated acceptable sensitivity and specificity by targeting 16S rRNA transcript copies of A. 
marginale in blood (Reinbold et al., 2010c).  For detection of A. marginale in infected animals, 
primers targeting Msp4 and Msp1a genes have been used to distinguish among different 
Anaplasma species and strains. (de la Fuente, 2001a). Another common target was the highly 
conserved Msp5 gene; however, in areas where multiple Anaplasma spp existed, there can be 
challenges with cross-reactively among related species (Visser et al., 1992). However, in the 
United States, only A. marginale is known to infect cattle; therefore, the necessity of 
discriminating between multiple Anaplasma spp. is of limited importance. 
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 Epidemiology and Strain Diversity 
Bovine anaplasmosis occurs worldwide in tropical and subtropical regions on six 
continents and throughout the United States (de la Fuente et al., 2007; Hove et al., 2018). Bovine 
anaplasmosis is endemic in the southeastern part of the United States but it has also been 
identified in every state but Hawaii (McCallon, 1973). The widespread nature of this disease is 
likely due to the frequent and extensive transportation of cattle across the country and the 
expansive distribution of competent tick vectors.  
Anaplasmosis was first recognized in the United States by P.B. Darlington in 1926 when 
he reported that southeastern Kansas cattle “had a febrile disease that usually occurs in the late 
summer and fall of the year” (Darlington, 1926). A herd-level A. marginale infection prevalence 
survey performed in Kansas from 2016-2017 found that herd-level A. marginale seroprevalence 
ranged from 19.8 to 34.4%, 44.2 to 57.3%, and 76.9 to 87.3% in the western, central, and eastern 
thirds of the state, respectively (Spare et al., 2020). Another recent seroprevalence survey was 
performed in Texas that evaluated individual animals by examining 1835 serum samples 
collected from 23 sale barns across the state. The results yielded a statewide A. marginale 
seroprevalence of 15.02% with the greatest seroprevalence, 20-38%, in the western portion of the 
state (Hairgrove et al., 2014). The previously mentioned seroprevalence of A. marginale in Texas 
was supported by Okafor and co-workers who found a seroprevalence of 13.25% among samples 
collected from a Texas slaughter facility and from samples submitted to the Texas A&M 
Veterinary Medical Diagnostic Laboratories between January 2002 and June 2012 (Okafor et al., 
2018b). In a similarly constructed survey, Okafor and co-workers later found the A. marginale 
seroprevalence in Mississippi to be 28.99% (Okafor et al., 2019b). Statewide A. marginale 
seroprevalences of approximately 4 and 11% were also documented for Georgia and Kentucky, 
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respectively (Okafor et al., 2018a and 2019a). These surveys collectively described different risk 
factors for A. marginale prevalence in beef cattle including, distribution of known vectors due to 
geographical location (Hairgrove et al., 2014; Spare et al., 2020), density of cattle population 
(Okafor 2018a,b and 2019b), animal age (Okafor et al., 2019a), and season (Okafor 2018a and 
2019a).  
 
Hundreds of strains of A. marginale have been identified from multiple geographical 
regions around the world. Structural differences in  major surface proteins (Msp) can influence 
the ability of different A. marginale strains to be transmitted and cause infection. Six Msp’s were 
identified by Palmer et al. (1999) as being useful to discriminate between strains; Msp1a was 
proposed as being most useful because it is only found in A. marginale and not other Anaplasma 
spp. Strain diversity among A. marginale is most commonly defined by the organization of the 
tandem repeat region of Msp1a. Individual repeats range in length from 28-29 amino acids and 
are given a unique alpha or alpha-numeric name. The sequential arrangement of these repeats 
Location Prevalence (%) Active/Retrospective Operation type # and type of sample Diagnostic type Reference
Georgia 4.44 Active Sale barn/slaughter 293 cows cELISA Okafor et al., 2019a
28.99 Active Slaughter facility 207 cows cELISA
22.11 Retrospective VDLs 5182 records cELISA
13.49 Active Slaughter facility 215 cows cELISA
13.02 Retrospective VDL 15,460 records cELISA
Texas 15.02 Active Sale barn 1835 cattle cELISA Hairgrove et al., 2014
10.78 Active Slaughter facility 232 cows cELISA
11.58 Retrospective VDL 2573 records cELISA
Kansas 51.7 Active Cow/calf 925 herds cELISA Spare et al. 2020
Kentucky Okafor et al., 2018b
Anaplasma marginale  Seroprevalence 
Mississippi Okafor et al., 2019b
Texas Okafor et al., 2018a
Table 1.1 – Statewide A. marginale seroprevalence surveys. Contemporary (post-2000) U.S. 
anaplasmosis seroprevalence surveys. Some surveys examine individual animal seroprevalence 
and some examine herd-level seroprevalence. 
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(Figure 1.4) in the tandem repeat region are used to define the Msp1a genotype (de la Fuente et 
al., 2001a). Major surface protein 1a was shown to be an adhesion for tick cells and bovine 
erythrocytes (de la Fuente et al., 2005) and to contribute to A. marginale infection immunity in 
cattle (Kocan et al., 2003). The Msp1a genotype is frequently used to define ‘strain’, such that 
‘strain’ is often synonymous with ‘Msp1a genotype’ for many A. marginale ‘strains’. Multiple A. 
marginale genotypes may co-exist within a host (bovine or tick); moreover, some A. marginale 
isolates contain multiple A. marginale Msp1a genotypes/strains. 
 
Worldwide geographical diversity of A. marginale was recently reviewed with records 
for over 350 A. marginale Msp1a genotypes (de la Fuente et al., 2007; Catanese et al., 2016; 
Hove et al., 2018). In China, 61 differing A. marginale genotypes were identified based on 
Msp1a genotyping (Yang et al., 2017). A total of 190 different genotypes of A. marginale, 188 of 
them being unique, were later identified in South Africa alone (Hove et al., 2018). Catanese et al. 
(2016) reviewed identification of 43 unique A. marginale genotypes in the United States. At least 
Figure 1.4 – Schematic representation of Msp1a tandem repeat region used for 
strain genotyping. Schematic organization of Msp1a variable tandem repeat region 
where “A” and “B” represent individual tandem repeats such that the Msp1a genotype 
of the example depicted above would be A B B (A, B2). 
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11 of the 43 identified genotypes of A. marginale in the United States were identified in a single 
herd at Kansas State University (Palmer et al., 2004). 
Genetically unique strains of A. marginale differ in transmissibility, disease 
characteristics, antigenicity, and susceptibility to antimicrobial treatments. One strain of A. 
marginale from Florida was not transmissible by Dermacentor variabilis ticks, an uncommon 
characteristic of A. marginale, whereas an Oklahoma strain was transmissible in the same 
experiment (de la Fuente et al., 2001b). Coetzee et al. (2006) assessed antimicrobial efficacy of 
three antimicrobial products against two A. marginale strains, Virginia and Oklahoma. They 
reported greater susceptibility of the Virginia strain to an oxytetracycline antimicrobial treatment 
regimen, compared with the Oklahoma strain (Coetzee et al., 2006). In an experiment designed 
to produce a viable vaccine candidate, Hammac et al. (2013) documented differing infection 
kinetics between an A. centrale strain and the St. Maries A. marginale strain, with A. centrale 
producing less severe clinical symptoms.  
Transmission 
 Transmission of A. marginale from an infected animal to a susceptible animal can be 
achieved through ticks and blood-contaminated fomites; however, tick transmission is more 
efficient and effective due to the replication and propagation of the pathogen within the tick. 
Ticks ingest infected erythrocytes while feeding on an infected host animal. In the tick, A. 
marginale first colonizes the midgut epithelium and then disperses to the salivary glands. When 
the tick takes another bloodmeal, this signals A. marginale to continue replicating in the salivary 
glands and, while the tick is still feeding, A. marginale is dispensed via tick saliva into the new 
host (Kocan et al., 1992). Lohr et al. (2002) found that A. marginale levels in the salivary glands 
can reach 104 to 105 bacteria / salivary gland. About 20 species of tick were reported to be 
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competent vectors of A. marginale (Kocan et al., 2004), but the two most prominent tick species 
found to transmit A. marginale in the United States were D. variabilis (Figure 1.5) and D. 
andersoni (Figure 1.6; Scoles et al., 2005). Male ticks appear to be the primary vector for 
transmission as they intermittently feed, first to finish sexually maturing and then later after 
locating and mating with a female tick. If the male tick first feeds on an infected host and then 
finds a female tick on a naïve host, transmission of A. marginale occurs when the male tick 
attaches and feeds on the naïve host after mating (Stiller et al., 1989).  
 
Figure 1.5 – Distribution and image of D. variabilis in the U.S. Images (distribution map-left; 
female D. variabilis tick-right) modified from CDC. 
Figure 1.6 – Distribution and image of D. andersoni in the U.S. Images (distribution map-left; 
male D. andersoni tick-right) modified from CDC. 
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 Kocan et al. (1990) confirmed transmission competence of D. andersoni for A. marginale 
when they acquisition-fed ticks on calves with ascending parasitemia for seven days. The ticks 
were removed, held for another seven days in a humidity chamber, then placed on naïve calves. 
The naïve calves developed clinical disease after an incubation period of about 25 days. 
Subsequently, D. andersoni and D. variabilis ticks were collected from an area in Canada where 
cattle were free of anaplasmosis and fed them on A. marginale infected animals. The ticks were 
then placed on naïve splenectomized calves that later developed A. marginale infection, 
confirming the competence of different geographic populations of D. andersoni and D. variabilis 
ticks to transmit A. marginale (Lankester et al., 2007). In a later experiment, acquisition-fed D. 
andersoni ticks on mammalian hosts known to be superinfected with two genetically distinct 
strains of A. marginale were found to be coinfected with both strains. These researchers reported 
subsequent successful transmission of both strains from tick to susceptible calves (Leverich et 
al., 2008).  
 Biological transmission through ticks is the primary mode of transmission of A. 
marginale as ticks can acquire and efficiently transmit the pathogen from animals in the acute or 
persistent phase of infection, but mechanical transfer of infected erythrocytes from an infected 
animal to a naïve animal has also been documented. Mechanical transmission can occur through 
blood contaminated fomites such as needles, dehorning equipment, castration equipment, ear 
taggers, tattoo equipment, or any other management practice that exposes naïve animals to 
erythrocytes from an infected animal. Mechanical transmission is less effective as there is no 
pathogen replication.  
 In an experimental setting, needle inoculation was shown to result in A. marginale 
transmission in 60% of animals stuck with a needle immediately after the needle had been used 
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on an acutely A. marginale-infected animal (Reinbold et al., 2010a). Though the percentage of 
transmission was high in that experiment, note should be taken that the needle was injected into 
the acutely infected animal each time before subsequent injection into naïve animals. This 
experiment demonstrated the likelihood of a naïve animal being infected if the animal being 
injected before is acutely A. marginale-infected and needles are not changed between animals.  
The Beef Quality Assurance (BQA) training program available to beef producers suggests that 
needles be changed every five animals, or immediately after damage to or dulling of needle. The 
previously mentioned experiment did not assess the likelihood of needle transmission of A. 
marginale from persistently infected animals to naïve animals, and as most A. marginale-
infected animals exist in the persistent phase of infection, risk of needle transmission in cattle 
production is largely unknown. 
 Mechanical transmission of A. marginale may also be facilitated by certain biting/sucking 
fly species. In experimental settings, Tabanus fuscicostatus (horse fly) and Stomoxys calcitrans 
(stable fly), two of the more important fly species in bovine health, have been implicated in 
transmission of A. marginale. An early fly-transmission experiment demonstrated the 
competence of certain species of horse flies to transmit A. marginale (Howell et al., 1941); 
however, this experiment was conducted under a laboratory setting using an unnaturally large 
number of flies. In a more recent series of A. marginale fly-transmission experiments by Scoles 
et al. (2005 and 2008), T. fuscicostatus and S. calcitrans were unable to transmit A. marginale. 
These researchers compared the efficiencies of transmission between D. andersoni ticks and 
stable flies and reported that stable flies were not competent vectors of A. marginale at a 
parasitemia 300-fold greater than the appreciated infectious dose. Conversely, D. andersoni ticks 
were successfully able to acquire and transmit A. marginale between these same animals (Scoles 
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et al., 2005).  Horse fly transmission competence was later compared to D. andersoni 
transmission competence by the same research group (Scoles et al., 2008). They report a failure 
of fly-borne mechanical transmission from an animal in acute disease while D. andersoni 
successfully transmitted from the same animal once it had reached a persistent phase of 
infection. Though these experiments noted failure of fly-borne A. marginale transmission, there 
may be differences in mechanical transmission competence among genetically differing strains 
of A. marginale. Recent experiments by Scoles et al. (2005 and 2008) did not take into account 
multiple days of consistent feeding on acutely infected animals that can take place in a natural 
setting. Despite conflicting results, it seems that if fly-transmission were to commonly occur, 
then the prevalence of A. marginale within infected herds would be much greater due to the 
number of flies that can be found on animals throughout the vector season. 
 Prevention, Treatment, and Control 
Prevention and control of A. marginale transmission is complex and difficult. Control of 
vector transmission relies on limiting the risk of exposure to ticks, biting flies, and blood-
contaminated processing equipment. Flies can be controlled through use of insecticides in pour-
on and drip products, feed-through products, and coated ear tags. Maintenance and upkeep of 
cattle living and feeding areas, which are favorable habitats for flies, are another important 
practice for limiting exposure of animals to fly populations. Ticks, the biological vectors of A. 
marginale, are not as easily eradicated or controlled (Jongejan and Uilenberg, 2004). Use of 
acaricides and pesticides for tick and fly control are an option, but vector resistance to these 
products should be considered. Application of these products during vector season is labor-
intensive and requires frequent retreatment to remain effective. This is not ideal for producers as 
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animals are not gathered for other management practices often enough to meet the demand of the 
product.  
Implementation of management practices such as disinfection and cleaning of production 
instruments between animals can greatly reduce the risk of A. marginale transmission within a 
herd by lysing the red blood cell which effectively kills the pathogen. The work of Reinbold et 
al. (2010) highlighted the importance of implementing a single-use needle practice when 
administering immunizations, antimicrobials, or other medications for management purposes. 
Implementing bio-secure production practices greatly reduces the risk of mechanically 
transmitting A. marginale within a herd. These practices may be the easiest to implement and 
add minimal extra time and cost during processing. 
 Antimicrobial-based anaplasmosis treatment and control is permitted in the United States 
with the use of tetracyclines. Table 1.2 contains an earlier list of antibiotic treatment regimen 
options for management of anaplasmosis in beef cattle (Richey and Palmer, 1990). This table 
contains recommendations that were historically accepted and utilized by veterinary 
professionals and producers. With increased concern of antimicrobial resistance (AMR), 
restrictions on antimicrobial usage (AMU), especially when delivered in feed products, have 
been put in place. Many of these treatment regimens are now extra-label and considered illegal. 
The currently approved antimicrobial treatment and control regimens are listed in Table 1.3. The 
United States Food and Drug Administration (FDA) has approved the use of oxytetracycline 
(OTC; FDA: 21 CFR 522.1660a) for treatment of anaplasmosis and chlortetracycline (CTC; 
FDA: 21 CFR 558.128) for control of active infection of anaplasmosis caused by A. marginale. 
Injectable oxytetracycline for the treatment of anaplasmosis is approved at 5-9 mg/lb of BW. For 
a single treatment of 9 mg/lb of BW, an animal could receive up to 100 mg of oxytetracycline in 
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a single injection. Per BQA suggestions of 10 mg per injection site, this animal would need to be 
needle-penetrated 10 different times in 10 different locations to fully-administer the treatment. 
This is not ideal as risk of injection site lesions increases. Use of CTC for control of active 
infection of anaplasmosis is approved at two dosages. It can be hand-fed at 0.5 mg/lb of BW 
daily or fed free-choice at 0.5-2.0 mg/lb of BW daily.  
 
 Although CTC fed free-choice is easy to implement, it is a costly management practice 
for producers (see Economic impact). Implementation of CTC into a management program also 
requires a Veterinary Feed Directive (VFD; FDA 21 CFR 558.6) approved and written by a 
producer’s partnering veterinarian. A veterinary-client-patient-relationship (VCPR) is necessary 
Use & Drug Route Dose (mg/lb. BW) Fequency of Treatment
Prevention
Chlortetracycline* Oral 0.10-0.25 Daily year-round
Chlortetracycline Oral 0.50 Daily during vector season
Oxytetracycline (50-100 mg/ml)* IV or IM 3.0-5.0 Every 28 days during vector season
Oxytetracycline (LA-200)* IV 9.0 Every 28 days during vector season
Carrier Elimination
Chlortetracycline* Oral 0.5 Daily for 120 days
Chlortetracycline* Oral 5.0 Daily for 60 days
Oxytetracycline (50-100 mg/ml)* IV or IM 5.0 Daily for 10 days
Oxytetracycline (50-100 mg/ml)* IV or IM 10.0 Daily for 5 days
Oxytetracycline (LA-200)* IM 9.0 4 RX at 3 day intervals
Treatment of Sick Animals
Oxytetracycline (50-100 mg/ml) IM 5.0 Usually one treatment
Oxytetracycline (LA-200) IM 9.0 One treatment
Temporary Protection During Outbreaks
Oxytetracycline (50-100 mg/ml)* IM 5.0 One treatment
Oxytetracycline (LA-200)* IM 9.0 One treatment
Prolonged Protection During Outbreaks
Oxytetracycline (50-100 mg/ml)* IM 5.0 Every 28 days during vector season
Oxytetracycline (LA-200)* IM 9.0 Every 28 days during vector season
Chlortetracycline Oral 0.50 Daily for 60 days
Antibiotic Treatment Regimens for Anaplasmosis Management
Table 1.2 - Historic antibiotic treatment regimens. Adapted from “Anaplasmosis in beef 
cattle” by Ron Gill; Texas Agricultural Extension Service. (*regimens are now extra-label and 
considered illegal.) 
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when considering the aforementioned antimicrobial usages for treatment and control. Depending 
on operation type and production goals, implementation of a specific antimicrobial treatment 
plan may differ between producers. There are no specifically approved drugs for clearance of A. 
marginale infection at the time of this writing. Several experiments investigating whether OTC 
or CTC treatment regimens were capable of clearing A. marginale infection have been conducted 
with mixed results that may or may not be representative of contemporary circulating strains of 
the pathogen (Kuttler et al., 1980; Coetzee et al., 2005 and 2006; Reinbold et al., 2010b). 
Tetracycline antimicrobials have been used increasingly over the last 50 years and susceptibility 
differences to these antimicrobials between some A. marginale strains have been documented. 
Pathogen diversity and continuous tetracycline use in cattle have likely further increased 
selection pressure on A. marginale strains to become more resistant to these antimicrobials. 
Continuous selection pressure and AMR concerns point out the need for research on 
contemporary strains to evaluate their susceptibility to approved antimicrobial treatment 
regimens.  
  
Work has also been conducted to develop an effective vaccine for prevention of infection 
and acute disease; however, the genetic diversity of A. marginale presents a significant obstacle 
Use & Drug Route Dose (mg/lb. BW) Fequency of Treatment
Control of active A. marginale  infection
Chlortetracycline Oral - Hand fed 0.5 Daily year-round
Chlortetracycline Oral - Free Choice** 0.5-2.0 Daily year-round
Treatment of Sick Animals
Oxytetracycline (50-100 mg/ml) IM 5.0
Oxytetracycline (LA-200) IM or SQ 9.0 One treatment
** - Must be manufactured in accordance with a Blue Bird Label 
Antibiotic Treatment Regimens for Anaplasmosis Management
Usually one treatment, no more than 
4 consecutive days
Table 1.3 – Current FDA-approved antibiotic treatment regimens. List of current approved 
anaplasmosis-based antimicrobial treatment (21 CFR 522.1660a) and control (21 CFR 558.128) 
strategies (FDA). 
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to developing a broadly effective vaccine capable of protecting animals against multiple A. 
marginale strains. Vaccine work for A. marginale was first initiated by Sir Arnold Theiler in 
1911 when he made the distinction between what he called “A. marginale proper” and “A. 
marginale (variety centrale)”. He questioned whether A. marginale (variety centrale) would 
confer immunity against an ‘A. marginale proper’ infection. Theiler experimented with this 
hypothesis and concluded that “the previous inoculation of A. marginale (variety centrale) gave 
sufficient immunity to protect the animals from a severe attack of anaplasmosis” (Theiler, 1911). 
The practice of vaccinating animals with a live vaccine is widely utilized in few countries across 
the world but is not currently approved for use in the United States (Hammac et al., 2013).  
There are no fully USDA-licensed vaccines for anaplasmosis at the time of this writing; 
however, an experimentally licensed vaccine that used an inactivated strain of A. marginale (i.e., 
Mississippi) became available in 2007 that claims to provide protection against clinical bovine 
anaplasmosis (Luther, 2007). Efficacy data on this vaccine is not available. In lieu of a fully 
USDA-approved vaccine, beef producers are left to rely largely on the use of antimicrobials for 
treatment and control.  
 Economic Impact 
Calculating a precise economic impact of tick-borne disease on livestock production 
worldwide has proven difficult, due to the complexity of the diverse parameters used in the 
calculations and the number of variables that influence tick-borne pathogen treatment and 
control. To understand the magnitude of the economic cost of ticks and tick-borne diseases on 
livestock, it was estimated that 80% of the world’s cattle are infected or at risk of tick-borne 
pathogens and that the annual cost to the global cattle industry approaches $19 billion per year 
(Mack, 2016).  Of the tick-borne pathogens that affect cattle, A. marginale is the most common 
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and widespread, infecting cattle on six continents. For anaplasmosis specifically, economic loss 
encompasses the cost of treatments, losses due to mortality and abortions, reduction in milk 
production, and reduced weight gain (Kocan et al., 2003).  
In 1973, B.R. McCallon stated that the original estimated annual economic loss to the 
beef industry in the United States of $35 million “was no longer realistic”. He concluded by 
adding that he “would hazard a guess” that anaplasmosis was costing the U.S. beef industry 
about $100 million annually (McCallon, 1973). In 2003, Kocan et al., updated McCallon’s 
original cost estimate of bovine anaplasmosis in the United States beef industry to be greater 
than $300 million annually (Kocan et al., 2003). In Latin America, an $800 million annual loss to 
the cattle industry from bovine anaplasmosis was calculated (Lombardo, 1975). Efforts were 
made to calculate more accurate estimations for smaller samples sizes. In Texas, a survey 
estimated an individual clinical case of anaplasmosis to cost Texas cattle producers about $425. 
When this number was considered across the state for the span of a year, it was estimated the 
total annual economic cost to Texas cattle producers was approximately $8.96 million (Alderink 
and Dietrich, 1983). A similar survey conducted in California found that beef producers in that 
state suffered an annual loss in 1976 of about $5.25 million (Goodger et al., 1979). All these 
surveys considered the losses resulting from mortality, morbidity, and treatment costs.  
Today, the most commonly used practice for control of anaplasmosis is a free-choice 
medicated mineral. Providing free-choice mineral to grazing cattle is inherently expensive and 
with the addition of CTC, it becomes more expensive. Medicated mineral for grazing cows costs 
an average $0.12 more per pound than non-medicated mineral. A grazing animal consumes 
approximately 0.25 lbs of mineral per day during an average summer grazing season of 150 
days. Seasonally, this represents approximately $4.50/head in added costs (B. Greenwood, oral 
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communication, 2020). This is a relatively small added cost when considering total cow cost per 
year, but any additional costs added to production management decreases profit upon realization. 
As antimicrobials are currently the primary method of treatment and control for active A. 
marginale infection, emphasis has been placed on producer education. A survey performed with 
Tennessee cattle producers investigated attitudes and knowledge of producers regarding 
antimicrobial use (AMU) and antimicrobial resistance (AMR) (Ekakoro et al., 2019). The survey 
asked four questions: What are the opinions on factors driving AMU? What are the opinions on 
alternatives to antimicrobials? What is the level of knowledge and perceptions regarding AMU 
and AMR? What are the preferred avenues for receiving information on prudent AMU? What 
they found was that profitability of the operation was the driving factor in their decision to use 
antimicrobials. Most producers also noted that additional training on infection prevention and 
implementation of farm-level biosecurity programs would reduce AMU in operations. About 
80% of producers reported being at least moderately familiar with AMR and only about 25% 
believed there was an over-use of antimicrobials in beef production. The last question revealed 
that only 36% of producers preferred educational seminars as the route for receiving information 
prudent to AMU (Ekakoro et al., 2019).  
Bovine anaplasmosis continues to be an important hemolytic disease in cattle across the 
world. The difficulty in recognizing clinical symptoms without laboratory diagnostics and the 
genetic diversity of A. marginale strains multiplies the complexities of trying to treat, control, 
and prevent disease. Taking into consideration risk factors such as geographical location, 
climate, cattle density, vector populations, and age of cattle, producers can implement 
management strategies specific to their operations. Use of injectable oxytetracycline and feed-
grade chlortetracycline remain the primary method for treatment and control for active A. 
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marginale infection, as there are currently no fully FDA-approved vaccines. The historical and 
intensive use of tetracyclines in beef production, added to the complex genetic diversity of A. 
marginale strains, have likely placed selection pressures upon the pathogen.  Experiments 
evaluating contemporary A. marginale strains and their antimicrobial susceptibility are important 
to determine the efficacies of the currently approved antimicrobial treatments. In the following 
chapter, we isolate and characterize two contemporary A. marginale strains from a Kansas beef 
cow herd. These strains will be used to investigate the antimicrobial susceptibility of 
contemporary A. marginale strains, and ultimately contribute to data-driven antimicrobial-based 
anaplasmosis management strategies.  
  
21 
 
 Literature Cited 
Alderink FJ, Dietrich RA. Economic and epidemiological implications of anaplasmosis in 
 Texas beef cattle herds. Bulletin/Texas Agricultural Experiment Station; no. 1426. 
 1983. 
Catanese HN, Brayton KA, Gebremedhin AH. RepeatAnalyzer: a tool for analyzing and 
 managing short-sequence repeat data. BMC genomics. 2016 Dec;17(1):422. 
Centers for Disease Control. Regions where ticks live. [cited May 5, 2020]. Available at 
 https://www.cdc.gov/ticks/geographic_distribution.html. 
Coetzee JF, Apley MD, Kocan KM, Rurangirwa FR, Van Donkersgoed J. Comparison of  three 
 oxytetracycline regimens for the treatment of persistent Anaplasma marginale 
 infections in beef cattle. Vet Parasitol. 2005 Jan 4;127(1):61-73. 
Coetzee JF, Apley MD, Kocan KM. Comparison of the efficacy of enrofloxacin, imidocarb, and 
 oxytetracycline for clearance of persistent Anaplasma marginale infections in cattle. Vet 
 Ther. 2006 Dec 1;7(4):347. 
Darlington PB. Anaplasmosis in cattle (Galziete) found to exist in Kansas. North Am Vet 
 1926;7(6):39-41. 
de la Fuente J, Garcia-Garcia JC, Blouin EF, Rodríguez SD, García MA, Kocan KM. Evolution 
 and function of tandem repeats in the major surface protein 1a of the ehrlichial pathogen 
 Anaplasma marginale. Anim Health Res Rev. 2001a Dec;2(2):163-74. 
de la Fuente J, Garcia-Garcia JC, Blouin EF, McEwen BR, Clawson D, Kocan KM. Major 
 surface protein 1a effects tick infection and transmission of Anaplasma marginale. Int J 
 Parasitol. 2001b Dec 1;31(14):1705-14. 
22 
 
de la Fuente J, Lew A, Lutz H, Meli ML, Hofmann-Lehmann R, Shkap V, Molad T, Mangold 
 AJ, Almazán C, Naranjo V, Gortázar C. Genetic diversity of Anaplasma species major 
 surface proteins and implications for anaplasmosis serodiagnosis and vaccine 
 development. Anim Health Res Rev. 2005 Jun;6(1):75-89. 
de la Fuente J, Ruybal P, Mtshali MS, Naranjo V, Shuqing L, Mangold AJ, Rodríguez SD, 
 Jiménez R, Vicente J, Moretta R, Torina A. Analysis of world strains of Anaplasma 
 marginale using major surface protein 1a repeat sequences. Vet Microbiol. 2007 Jan 
 31;119(2-4):382-90. 
Ekakoro JE, Caldwell M, Strand EB, Strickland L, Okafor CC. A survey of antimicrobial use 
 practices of Tennessee beef producers. BMC Vet Res. 2019 Dec 1;15(1):222. 
Eriks IS, Palmer GH, McGuire TC, Allred DR, Barbet AF. Detection and quantitation of 
 Anaplasma marginale in carrier cattle by using a nucleic acid probe. J Clin Microbiol. 
 1989 Feb 1;27(2):279-84. 
French DM, McElwain TF, McGuire TC, Palmer GH. Expression of Anaplasma marginale 
 major surface protein 2 variants during persistent cyclic rickettsemia. Infect Immun. 
 1998 Mar 1;66(3):1200-7. 
Food and Drug Administration. Section 522.1660a; Oxytetracycline solution, 200 
 milligrams/milliliter. [cited May 5, 2020]. Available at https://www.accessdata.fda.gov/ 
 scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=522.1660a. 
Food and Drug Administration. Section 558.6; Veterinary feed directive drugs. [cited May 5, 
 2020]. Available at https://www.govinfo.gov/content/pkg/CFR-2019-title21-vol6/xml/CF 
 R-2019-title21-vol6-part558.xml#seqnum558.6. 
23 
 
Food and Drug Administration. Section 558.128; Chlortetracycline. [cited May 5, 2020]. 
 Available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cf 
 m?fr=522.1660a. 
Goodger WJ, Carpenter T, Riemann H. Estimation of economic loss associated with 
 anaplasmosis in California beef cattle. J Am Vet Med Assoc. 1979 Jun;174(12):1333-6. 
Hairgrove TB, Craig TM, Budke CM, Rodgers SJ, Gill RJ. Seroprevalence of Anaplasma 
 marginale in Texas cattle. Prev Vet Med. 2014 Sep 1;116(1-2):188-92. 
Hammac GK, Ku PS, Galletti MF, Noh SM, Scoles GA, Palmer GH, Brayton KA. Protective 
 immunity induced by immunization with a live, cultured Anaplasma marginale strain. 
 Vaccine. 2013 Aug 2;31(35):3617-22. 
Hashem M, Neamat-Allah AN, Gheith MA. A study on bovine babesiosis and treatment with 
 reference to hematobiochemical and molecular diagnosis. Veterinary Medicine In-
 between Health & Economy (VMHE). 2018 Nov 9;55. 
Hove P, Chaisi ME, Brayton KA, Ganesan H, Catanese HN, Mtshali MS, Mutshembele AM, 
 Oosthuizen MC, Collins NE. Co-infections with multiple genotypes of Anaplasma 
 marginale in cattle indicate pathogen diversity. Parasit Vectors. 2018 Dec 1;11(1):5. 
Howell DE, Sanborn CE, Rozeboom LE, Stiles GW, Moe LH. The transmission of anaplasmosis 
 by horseflies (Tabanidae). Okla. A&M College, Tech. Bull. 1941. 
Jongejan F, Uilenberg G. The global importance of ticks. Parasitol. 2004 Oct;129(S1):S3-14. 
Jones EW, Brock WE. Bovine anaplasmosis - its diagnosis treatment and control. J Am Vet Med 
 Assoc. 1966 Jan 1;149(12):1624-1633.  
Kieser ST, Eriks IS, Palmer GH. Cyclic rickettsemia during persistent Anaplasma marginale 
 infection of cattle. Infect Immun. 1990 Apr 1;58(4):1117-9. 
24 
 
Knowles D, De Echaide ST, Palmer G, McGuire T, Stiller D, McElwain T. Antibody against an 
 Anaplasma marginale MSP5 epitope common to tick and erythrocyte stages identifies 
 persistently infected cattle. J Clinical Microbiol. 1996 Sep 1;34(9):2225-30. 
Kocan KM, Yellin TN, Claypool PL, Barron SJ, Ewing SA, Hair JA. Development and 
 infectivity of Anaplasma marginale in Dermacentor andersoni nymphs. Am J Vet Res. 
 1990 Aug;51(8):1292-4. 
Kocan KM, Stiller D, Goff WL, Claypool PL, Edwards W, Ewing SA, McGuire TC, Hair JA, 
 Barron SJ. Development of Anaplasma marginale in male Dermacentor andersoni 
 transferred from parasitemic to susceptible cattle. Am J Vet Res. 1992 Apr;53(4):499-
 507. 
Kocan KM, De la Fuente J, Guglielmone AA, Meléndez RD. Antigens and alternatives for 
 control of Anaplasma marginale infection in cattle. Clin Microbiol Rev. 2003 Oct 
 1;16(4):698-712. 
Kocan KM, De La Fuente J, Blouin EF, Garcia-Garcia JC. Anaplasma marginale (Rickettsiales: 
 Anaplasmataceae): recent advances in defining host–pathogen adaptations of a tick-borne 
 rickettsia. Parasitol. 2004 Oct;129(S1):S285-300. 
Kuttler KL, Simpson JE. Relative efficacy of two oxytetracycline formulations and doxycycline 
 in the treatment of acute anaplasmosis in splenectomized calves. Am J Vet Res. 1978 Jan 
 31;39(2):347-349. 
Lankester MW, Scandrett WB, Golsteyn-Thomas EJ, Chilton NC, Gajadhar AA. Experimental 
 transmission of bovine anaplasmosis (caused by Anaplasma marginale) by means of 
 Dermacentor variabilis and D. andersoni (Ixodidae) collected in western Canada. Can J 
 Vet Res. 2007 Oct;71(4):271. 
25 
 
Leverich CK, Palmer GH, Knowles DP, Brayton KA. Tick-borne transmission of two genetically 
 distinct Anaplasma marginale strains following superinfection of the mammalian 
 reservoir host. Infect Immun. 2008 Sep 1;76(9):4066-70. 
Löhr CV, Rurangirwa FR, McElwain TF, Stiller D, Palmer GH. Specific expression of 
 Anaplasma marginale major surface protein 2 salivary gland variants occurs in the 
 midgut and is an early event during tick transmission. Infect Immun. 2002 Jan 
 1;70(1):114-20. 
Lombardo RA. Socio-economic importance of the tick problem in the Americas. In: Reunion 
 Interamericana a Nivel Ministerial sobre el Control de la Fiebre Aftosa y Otras Zoonosis, 
 Guatemala City, 16 Apr 1975. 
Luther, GD. History of our anaplasmosis vaccine. 14 Jan 2019 [cited 6 Apr 2020]. Available 
 from: http://www.anaplasmosisvaccine.com 
Mack A. Global health impacts of vector-borne diseases: workshop summary (2016). In: Global 
 health impacts of vector-borne diseases: workshop summary (2016). 2016. National 
 Academies Press. 
McCallon BR. Prevalence and economic aspects of anaplasmosis. In: Proceedings of the 6th 
 National Anaplasmosis Conference. Heritage Press, Stillwater, Okla 1973 Mar 19:1-
 3. 
Okafor CC, Collins SL, Daniel JA, Harvey B, Sun X, Coetzee JF, Whitlock BK. Factors 
 associated with seroprevalence of Anaplasma marginale in Kentucky cattle. Vet 
 Parasitol Reg Stud Reports. 2018a Aug 1;13:212-9. 
26 
 
Okafor CC, Collins SL, Daniel JA, Harvey B, Coetzee JF, Whitlock BK. Factors associated with 
 seroprevalence of bovine anaplasmosis in Texas. Vet Parasitol Reg Stud Reports. 2018b 
 Dec 1;14:32-40. 
Okafor CC, Collins SL, Daniel JA, Coetzee JF, Whitlock BK. Seroprevalence of bovine 
 Anaplasmosis in Georgia. Vet Parasitol Reg Stud Reports. 2019a Jan 1;15:100258. 
Okafor CC, Collins SL, Daniel JA, Coetzee JF, Whitlock BK. Factors associated with 
 seroprevalence of bovine anaplasmosis in Mississippi, USA. Vet Parasitol Reg Stud 
 Reports. 2019b Aug 1;17:100301. 
Palmer GH, Rurangirwa FR, Kocan KM, Brown WC. Molecular basis for vaccine development 
 against the ehrlichial pathogen Anaplasma marginale. Parasitol Today. 1999 Jul 
 1;15(7):281-6. 
Palmer GH, Brown WC, Rurangirwa FR. Antigenic variation in the persistence and transmission 
 of the ehrlichia Anaplasma marginale. Microbes Infect. 2000 Feb 1;2(2):167-76. 
Palmer GH, Knowles DP, Rodriguez JL, Gnad DP, Hollis LC, Marston T, Brayton KA. 
 Stochastic transmission of multiple genotypically distinct Anaplasma marginale strains in 
 a herd with high prevalence of Anaplasma infection. J Clin Microbiol. 2004 Nov 
 1;42(11):5381-4. 
Potgieter FT, Stoltsz W. Bovine anaplasmosis. Infectious diseases of livestock. 2004;1:594-616. 
Reinbold JB, Coetzee JF, Hollis LC, Nickell JS, Riegel C, Olson KC, Ganta RR. The efficacy of 
 three chlortetracycline regimens in the treatment of persistent Anaplasma marginale 
 infection. Vet Microbiol. 2010a Sep 28;145(1-2):69-75. 
27 
 
Reinbold JB, Coetzee JF, Hollis LC, Nickell JS, Riegel CM, Christopher JA, Ganta RR. 
 Comparison of iatrogenic transmission of Anaplasma marginale in Holstein steers via 
 needle and needle-free injection techniques. Am J Vet Res. 2010b Oct;71(10):1178-88. 
Reinbold JB, Coetzee JF, Sirigireddy KR, Ganta RR. Detection of Anaplasma marginale and A. 
 phagocytophilum in bovine peripheral blood samples by duplex real-time reverse 
 transcriptase PCR assay. J Clin Microbiol. 2010c Jul 1;48(7):2424-32. 
Richey EJ, Palmer GH. Bovine anaplasmosis. Compendium on Continuing Education for the 
 Practicing Veterinarian. 1990;12(11):1661-8. 
Scoles GA, Broce AB, Lysyk TJ, Palmer GH. Relative efficiency of biological transmission of 
 Anaplasma marginale (Rickettsiales: Anaplasmataceae) by Dermacentor andersoni 
 (Acari: Ixodidae) compared with mechanical transmission by Stomoxys calcitrans 
 (Diptera: Muscidae). J Med Entomol. 2005 Jul 1;42(4):668-75. 
Scoles GA, Miller JA, Foil LD. Comparison of the efficiency of biological transmission of 
 Anaplasma marginale (Rickettsiales: Anaplasmataceae) by Dermacentor andersoni stiles 
 (Acari: Ixodidae) with mechanical transmissions by the horse fly, Tabanus fuscicostatus 
 hine (Diptera:Muscidae). J Med Entomol. 2008;45(1):109-114. 
Smith T, Kilborne FL. Investigations into the nature, causation, and prevention of Texas or 
 southern cattle fever. US Department of Agriculture, Bureau of Animal Industry; 1893. 
Spare MR, Hanzlicek GA, Wootten KL, Anderson GA, Thomson DU, Sanderson MW, Ganta 
 RR, Reif KE, Raghavan RK. Bovine anaplasmosis herd prevalence and management 
 practices as risk-factors associated with herd disease status. Vet Parasitol X. 2020 May 
 1;3:100021. 
28 
 
Stiller D, Kocan KM, Edwards W, Ewing SA, Hair JA, Barron SJ. Demonstration of colonies of 
 Anaplasma marginale Theiler in salivary glands of three Dermacentor spp. infected as 
 either nymphs or adults. Am J Vet Res. 1989;50:1386-1391. 
Theiler A. Further investigations into anaplasmosis of South African cattle. Pretoria: Government 
 Printer and Stationery Office; 1911. 
Visser ES, McGuire TC, Palmer GH, Davis WC, Shkap V, Pipano E, Knowles DP. The Anaplasma 
 marginale msp5 gene encodes a 19-kilodalton protein conserved in all recognized 
 Anaplasma species. Infect Immun. 1992 Dec 1;60(12):5139-44. 
Yang J, Han R, Liu Z, Niu Q, Guan G, Liu G, Luo J, Yin H. Insight into the genetic diversity of 
 Anaplasma marginale in cattle from ten provinces of China. Parasit Vectors. 2017 Dec 
 1;10(1):565. 
 
 
  
29 
 
 
 
Chapter 2 - Isolation and characterization of two Anaplasma 
marginale isolates from a Kansas beef cattle herd 
 Abstract  
Bovine anaplasmosis is a tick-borne bacterial disease caused by Anaplasma marginale, a 
global pathogen estimated to cost the U.S. cattle industry >$300 million per year. Treatment and 
control strategies rely heavily on tetracycline antimicrobials; however, susceptibility differences 
among A. marginale strains to this antimicrobial class have been documented. Changes in 
susceptibility to tetracycline antimicrobials have likely increased from selective pressures 
associated with the intensive tetracycline use in cattle production over the last half century. 
Therefore, use of characterized contemporary strains are essential when evaluating or re-
evaluating antimicrobial-based anaplasmosis management strategies. The objective of this 
experiment was to locate and propagate two contemporary isolates of A. marginale actively 
circulating in Kansas cattle and characterize their virulence and infection kinetics in adult beef 
cows.  Contemporary A. marginale strains were identified from naturally infected adult beef 
cows in the Kansas State University Cow-Calf herd. Blood samples containing these unique 
isolates (KS1 and KS2), were collected, propagated in splenectomized calves, and stabilates 
were prepared as challenge material for adult beef cows. Virulence of isolates was characterized 
by progression of anemia whereas infection kinetics of isolates was evaluated by progression of 
bacteremia. Isolate KS1-challenged animals reached peak clinical anaplasmosis by 35 days post-
inoculation (dpi), ~3 days earlier than isolate KS2-challenged animals. KS1-challenged animals 
reached a peak bacteremia of 3.43×106 bacteria/mL of blood while isolate KS2-challenged 
animals reached a significiantly greater level of 9.46×108 bacteria/mL of blood . Although KS1 
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and KS2 had different infection kinetic profiles, both isolates produced clinical anasplasmosis in 
challenged animals that required treatment intervention. Results from this experiment 
demonstrate the virulence and infection kinetic profiles of two A. marginale isolates from 
different Msp1a genotype families. Characterized contemporary A. marginale isolates, such as 
KS1 and KS2, will be useful for future experiments seeking to evaluate or re-evaluate 
antimicrobial-based anaplasmosis management strategies.  
 Introduction 
Economic losses due to bovine anaplasmosis and implementation of anaplasmosis 
management strategies conservatively cost the U.S. cattle industry more than $300 million/year 
(McCallon 1973; Kocan et al., 2003). The causative agent of anaplasmosis is Anaplasma 
marginale, an obligate-intracellular rickettsial pathogen of several ruminant species. Found in 
cattle throughout six continents, A. marginale is likely the most prevalent tick-transmitted 
livestock disease worldwide (de la Fuente et al., 2007; Hove et al., 2018). In the United States, 
Dermacentor species ticks are the natural biological vectors of A. marginale (Kocan et al., 1992; 
Scoles et al., 2008). Mechanical transmission of A. marginale can also occur by blood-
contaminated fomites such as needles, dehorning and castration equipment, and biting flies 
(Hawkins et al., 1982; Scoles et al., 2005; Reinbold et al., 2010).  
Following transmission, A. marginale parasitizes bovine erythrocytes. After an 
incubation period of 6-70 days, the spleen rapidly destroys infected erythrocytes resulting in 
severe anemia, the hallmark of clinical disease (Kocan et al., 2003). Other symptoms of clinical 
disease can include fever, weight-loss, abortion, lethargy, and death in animals over 2 years of 
age (Kocan et al., 2003). Cattle that survive acute disease develop persistent infection and serve 
as reservoirs for subsequent transmission events. Antimicrobial treatment and control strategies 
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in the U.S. are limited to the use of injectable and feed-grade tetracyclines. The most common 
anaplasmosis management strategy used by cattle producers is chlortetracycline-medicated, free-
choice mineral offered to animals during seasons in which vectors are active. Other management 
strategies include using new needles for each animal, fly and tick management, herd biosecurity, 
disinfecting processing tools between animals, and implementing a diseased-animal culling plan. 
At this time, an anaplasmosis vaccine that is fully licensed by the FDA is not available. 
   Hundreds of genetically differing strains of A. marginale have been identified around the 
world. Genetic diversity of A. marginale is most-frequently characterized by examining the 
arrangement of short, tandemly-arranged repeat sequences in the variable region of the Major 
Surface Protein 1a (Msp1a) gene (msp1a), a putative surface protein involved with adhesion of 
A. marginale to host cells (de la Fuente et al., 2001a; 2003a). A recent review of A. marginale 
diversity identified over 350 Msp1a genotypes from around the world. The diversification of 
Msp1a may be attributed to long-term, continuous selection pressure from both human and 
natural sources (de la Fuente et al., 2003b); however, in repeated passage experiments between 
ticks and cattle, this gene remained a stable genetic A. marginale strain marker.  
Because A. marginale diversity is commonly defined by Msp1a genotype, the terms 
genotype (referring to Msp1a genotype) and strain are used synonymously in this manuscript. 
Strains can have important phenotypic differences that influence anaplasmosis disease dynamics 
and management strategies, such as differences in tick-transmissibility, antigenic characteristics, 
and antimicrobial susceptibility (Palmer et al., 2000; de la Fuente et al., 2001b; Coetzee et al., 
2006a,b). For example, the A. marginale Oklahoma strain was determined to be less susceptible 
than the Virginia strain when these pathogen strains were treated with different antimicrobial 
products during both in vitro and in vivo experiments (Coetzee et al., 2006a,b).  
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Intensive reliance on tetracycline antimicrobials to manage anaplasmosis, as well as 
several other cattle diseases, over the past half century has put enormous selection pressure on 
pathogens to evolve antimicrobial-resistance mechanisms. In addition, of all cattle diseases with 
tetracycline-use indications, only for anaplasmosis is there no legal limit on treatment duration. 
Thus, cattle may be treated with low-dose chlortetracycline year-round, provided that a cattle 
producer has a valid Veterinary Feed Directive. Heavy reliance on the use of tetracycline 
antimicrobials, especially feed-grade chlortetracycline to control active anaplasmosis and the 
notable diversity of A. marginale, highlight the necessity of having characterized, contemporary 
A. marginale strains for research aimed at evaluating or re-evaluating antimicrobial-based 
anaplasmosis control options. 
Anaplasmosis prevalence in the U.S. has been a subject of recent alarm to the nation’s 
beef producers; this alarm has, in part, been fueled by anecdotal reports of anaplasmosis 
treatment and control failures. Some anaplasmosis management failures may be due to A. 
marginale becoming tolerant to current legal antimicrobial management options. To evaluate or 
re-evaluate antimicrobial-based anaplasmosis management strategies, well-characterized 
contemporary A. marginale strains are necessary. Therefore, the objective of our experiment was 
to locate, identify, and propagate, two contemporary A. marginale field isolates and characterize 
their virulence and infection kinetics in naïve adult beef cows. We hypothesized that these A. 
marginale isolates, each from different Msp1a genotype families, would exhibit unique virulence 
and infection kinetics as measured by PCV and PCR, respectively. The data from our experiment 
will serve as a baseline for future research aimed at evaluating antimicrobial-based, 
anaplasmosis-management strategies.  
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 Materials and Methods 
Animal use 
The Kansas State University Institutional Animal Care and Use Committee and the 
Institutional Biosafety Committee reviewed and approved all animal handling and animal care 
practices used in our experiment. All animal procedures were conducted in accordance with the 
Guide for the Care and Use of Animals in Agricultural Research and Teaching (FASS, 2010).  
Anaplasma marginale isolate identification and collection 
Two adult beef cows (1-1018 and 1-0307) (Table 2.1) from the Kansas State University 
Cow-Calf Unit herd previously identified as naturally infected with different A. marginale 
Msp1a genotypes (Reif et al. unpublished) were selected as the source animals for A. marginale 
strain isolation. Cow 1-0307 was infected with Msp1a genotype B B, referred to hereafter as A. 
marginale isolate KS1. Cow 1-1018 was infected with Msp1a genotypes D D E, (K1) D D D E, 
and (K1) D D D D D E, referred to hereafter as A. marginale isolate KS2. Cows were restrained  
in squeeze chutes and ~60 mL of fresh blood was collected via jugular venipuncture into blood 
bags containing heparin for subsequent inoculation into splenectomized calves for A. marginale 
isolate propagation.  
Propagation of A. marginale isolates 
Two Holstein bull calves (Table 2.1), negative for A. marginale infection by PCR and 
cELISA, weighing approximately 57 kg, were splenectomized to propagate A. marginale field 
isolates KS1 and KS2. Isolates were propagated by inoculating splenectomized calves 15836 and 
15855 with 60 mL of freshly collected blood from cows 01-0307 and 01-1018, respectively. 
Calves were monitored daily for signs of clinical anaplasmosis (see Clinical virulence 
monitoring). Once A. marginale bacteremia peaked, or when clinically indicated, calves were 
34 
 
anesthetized under a general plane of anesthesia and 3 to 5 L of whole blood was harvested from 
the jugular vein into blood bags containing heparin sulfate at a concentration of 5 U heparin/mL 
blood. Immediately following blood collection and while still under anesthesia, animals were 
humanely euthanized. Blood was transported immediately on ice and stored at 4°C for stabilate 
preparation. 
 
Stabilate preparation 
Whole blood collected for stabilate production was aliquoted and centrifuged for 30 min 
at 1,000 × G to separate serum and red blood cells. Serum and buffy coat were removed, and the 
Animal ID Animal Type Strain Infection Source Genotype Analysis # Msp1a Genotypes
1-0307 Am strain source cow KS1 natural B B; 1
15836 splenectomized calf KS1 blood (1-0307) B B; 1
7379 challenged beef cow KS1 stabilate (An15836) B B; 1
7362 challenged beef cow KS1 stabilate (An15836) B B; 1
7096 challenged beef cow KS1 stabilate (An15836) B B; 1
7155 challenged beef cow KS1 stabilate (An15836) B B; 1
1-1018 Am strain source cow KS2 natural D D E; K1 D D D E; K1 
D D D D D E
3
15855 splenectomized calf KS2 blood (1-1018) K1 D D D D D E; K1 D 
D D E; K1 D D E
3
7338 challenged beef cow KS2 stabilate (An15855) K1 D D D D D E; K1 D 
D D E; K1 D D E
3
7311 challenged beef cow KS2 stabilate (An15855) D D E; K1 D E; K1 D D 
D E; K1 E
4
503 challenged beef cow KS2 stabilate (An15855) K1 D D D D D E; K1 D 
D D E; K1 D E; K1 E
4
7151 challenged beef cow KS2 stabilate (An15855) K1 D D D D D E; K1 D 
D E; K1 D E; K1 E
4
Table 2.1 – List of animals used in Chapter 2. List of animals used in the experiment, their 
purpose, which A. marginale strain they were infected with, what the source of infection was, 
and the Msp1a genotypes contained within each strain. (Am: Anaplasma marginale). 
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remaining red blood cells were washed three times with PBS and centrifuged for 30 min at 1,000 
× G following each wash. After the final wash, the packed red blood cells were mixed with a 
stabilate buffer (31.2% DMSO in 1× PBS) in a 1:1 ratio. The mixture was then aliquoted into 
cryotubes and stored in liquid nitrogen. 
Anaplasma marginale field-isolate challenge 
Ten adult, spleen-intact beef cows between the ages of two and five years were purchased 
and confirmed A. marginale negative by qPCR and cELISA. Cows were assigned randomly to 
two groups (n=4/group) with the remaining two animals serving as sentinels (Table 2.1). Cows 
in Group 1 were inoculated via jugular with 4 mL of the KS1 isolate stabilate diluted in equal 
parts with serum previously collected from the respective cow. Cows in Group 2 were inoculated 
with the KS2 isolate as described above. Blood samples were collected via coccygeal 
venipuncture at least weekly to monitor A. marginale bacteremia. The two main study 
parameters tracked were bacteremia and packed cell volume (PCV). Bacteremia was monitored 
over time to evaluate the infection kinetics of each field isolate; PCV was monitored also over 
time as the primary disease measurement and used to determine onset of anemia, hematocrit 
nadir, and need for treatment intervention. During sampling, cows with an observed rectal 
temperature over 104°F or a PCV below 14% were treated with subcutaneously administered 
oxytetracycline (9 mg/lb body weight; Bio-Mycin, Boehringer Ingelheim, Duluth, GA). 
Clinical virulence monitoring 
Animals challenged with A. marginale were monitored for overt clinical signs of 
anaplasmosis (e.g. elevated rectal temperatures, elevated respiration rates, depression, and 
anorexia). Blood samples were collected at least twice weekly from each animal via coccygeal 
venipuncture into 4 mL vacuette tubes containing EDTA to monitor the development of 
36 
 
bacteremia (see Pathogen detection) and anemia. The development of anemia was monitored by 
evaluating the PCV of each animal after every blood sample collection. Briefly, whole blood 
samples were drawn into capillary tubes, centrifuged in a micro-hematocrit centrifuge for 5 min 
and the percent of packed red cells in the samples were recorded. 
Quantitative PCR (qPCR) 
The development of bacteremia in A. marginale-challenged animals was monitored by 
qPCR. To determine bacteremia, DNA was extracted from 100 µL of whole blood using the 
Quick-gDNATM Miniprep Kit (Zymo Research, Irvine, CA) per manufacturer recommendations. 
Resulting DNA was eluted in 35 µL DNA Elution Buffer. Each qPCR reaction included: water, 
1X SsoAdvance Universal SYBRsupermix (Bio-Rad Laboratories, Hercules, CA), 10µM each of 
primer (Am msp5F and Am msp5R, Hammac 2013), and 2 µL of DNA. Samples were analyzed 
using a  CFX ConnectTM Real-Time System (Bio-Rad Laboratories, Hercules, CA) with the 
following cycling conditions: 98°C for two min, 40 cycles of 98°C for 5 sec, 60°C for 5 sec, and 
74°C for 15 sec; a final melt curve was included (65-95°C in 0.5°C increments). The CFX 
Maestro Software (Bio-Rad Laboratories, Hercules, CA) was used to display results. 
Percent parasitized erythrocyte (PPE) analysis 
Bacteremia was monitored by evaluating PPE. To estimate PPE, blood smears were 
prepared and stained using Hema 3TM stain (Fisherbrand, Pittsburgh, PA). At least two 
microscopic field views with a minimum of 100 red blood cells per field were evaluated to 
determine PPE. In each microscopic field view, the number of parasitized erythrocytes were 
divided by the total number of erythrocytes within the field view and multiplied by 100 to get the 
percentage of infected erythrocytes. An average percent of infected erythrocytes was calculated 
between the two microscopic field views for each sample.  
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Competitive enzyme-linked immunosorbent assay (cELISA) 
Serum samples from A. marginale-challenged animals were evaluated by cELISA for 
development of an A. marginale-specific immune response. Serum samples were submitted to 
the Iowa State University Veterinary Diagnostic Laboratory for evaluation using a commercial 
cELISA that detected antibodies specific to A. marginale Msp5 (VMRD Inc., Pullman, WA). 
The assay was conducted per manufacturer instructions and samples with a percent inhibition 
value greater than 30% were considered seropositive.   
Anaplasma marginale Msp1a genotype analysis 
To confirm the intended A. marginale strain/isolate was the source of disease in 
challenged cows, Msp1a genotyping was performed on blood from each challenged cow. Briefly, 
the amino terminus of the Msp1a gene was amplified as previously described (Palmer et al., 
2004). The resulting PCR product was cloned into a pCR™2.1-TOPO cloning vector and 
transformed into DH5ɑ™-TOP10 E. coli, according to manufacturer instructions (Invitrogen, 
Carlsbad, CA). A minimum of 10 resultant clones were screened for presence of the insert and a 
minimum of five positive clones were submitted for rolling cycle amplification (RCA) and 5’ 
and 3’ sequencing using T3 or T7 as sequencing primers (MC Lab, South San Francisco, CA).  
Statistical analysis 
Statistical analyses were performed using GraphPad Prism v7.01 (San Diego, CA). Two-
way analysis of variance (ANOVA) with Sidak correction for multiple comparisons was used to 
compare PCV, bacteremia, and PPE between KS1- and KS2-challenged animals. Linear 
regression was used to compare ascending bacteremia slopes between KS1 and KS2 inoculated 
animals. Unpaired, two-tailed t-tests with Welch’s correction were used to compare greatest 
hematocrit change, time to PCV nadir, peak bacteremia, and time to peak bacteremia between 
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KS1- and KS2-challenged animals. When protected by a significant F-test (i.e., < 0.05), 
differences were considered significant when P < 0.05.   
Sequences were analyzed both manually and using RepeatAnalyzer (Catanese et al., 
2016) to identify Msp1a genotypes. Only sequences containing the full tandem repeat region 
were included in the analysis. 
 Results  
 
Propagation of A. marginale isolates in splenectomized calves 
Isolates KS1 and KS2 were inoculated into two splenectomized calves (Table  2.1) to 
propagate the strains in order to characterize their infection kinetics and virulence in adult beef 
cows. During isolate propagation, both calves maintained rectal temperatures above 102.6°F; calf 
15836 spiked to 105.4° F on the day of euthanasia. Immediately prior to inoculation, starting 
PCV values for splenectomized calf 15836 and calf 15855 were 39% and 37%, respectively. Calf 
15836 was inoculated with KS1 and was euthanized 23 days post-infection (dpi) with a final 
PCV value of 18%, 25.8% PPE, and a bacteremia of 1.05 × 107 bacteria/mL (Table 2.2). Calf 
15855 was inoculated with KS2 and was euthanized 39 dpi with a final PCV value of 18%, 
18.3% PPE, and a bacteremia of 2.96 × 109 bacteria/mL (Table 2.2). Although the infection 
process was slower for calf 15855, bacteremia was first detected by qPCR in both calves at 8 dpi.  
 
Animal ID Strain Final PCV (%) Final PPE (%) Final bacteremia
15836 KS1 16 25.8 1.05 × 107
15855 KS2 18 18.3 2.96 × 109
KS1 and KS2 Strain Propagation
Table 2.2 – Strain propagation final values. Characteristics of infected 
blood used to prepare strain stabilates to be used as challenge material. 
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Assessment of A. marginale KS1 and KS2 isolate virulence in adult beef cows 
Adult beef cows were inoculated with prepared stabilates of A. marginale KS1 and KS2 
isolates (Table 2.1). Virulence of A. marginale KS1 and KS2 isolates was assessed by 
monitoring PCV and evaluating: i) time to initiation of anemia, ii) PCV nadir; iii) time to PCV 
nadir; and, iv) requirement for treatment intervention. Other virulence-related clinical parameters 
which were measured but not statistically analyzed due to sample size and high individual animal 
variability were rectal temperature, overt signs of respiratory distress, depression, and anorexia. 
Initial onset of anemia began 29 dpi and 33 dpi for cows challenged with KS1 and KS2, 
respectively. Overall mean hematocrit reduction (based on PCV data; Figure 2.1, Table 2.3) was 
similar for KS1-challenged (mean hematocrit reduction = 49.7%, SD ±4.9%) and KS2-
challenged (mean hematocrit reduction = 50.6%, SD ±10.8%) animals; animals in both groups 
experienced an average of 50% hematocrit reduction. Time to PCV nadir was significantly 
longer for KS2-challenged animals (mean = 37.5 dpi, SD ±1.0 dpi), compared with KS1-
challenged (mean = 35.3 dpi, SD ±1.3 dpi) animals. Three of four animals challenged with KS1 
and KS2 reached experiment-mandated parameters for oxytetracycline-treatment intervention. 
The ultimate virulence endpoint – death – was not evaluated in this study and animals were 
rescue-treated with injectable oxytetracycline when their PCV reached 18% or their temperature 
was >104.5°F. Rectal temperatures remained relatively normal throughout the experiment. 
Exceptions were cows 7379, 7338, and 503, that had one-time rectal temperatures over 103.0 F. 
No overt signs of respiratory distress, depression or anorexia were observed for any cow, even 
during peak of acute disease. 
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Assessment of A. marginale KS1 and KS2 isolate infection kinetics in adult beef 
cows 
Infection kinetics of KS1 and KS2 A. marginale isolates were assessed (Table 2.4; 
Figure 2.2) by evaluating: i) dpi to detectable infection by qPCR, ii) rate of ascending 
bacteremia; iii) peak bacteremia; and, iv) time to peak bacteremia. The percentages of parasitized 
Figure 2.1 – PCV of A. marginale-challenged animals. Changes in packed cell volume (PCV) 
over time where KS1-challenged animals are represented by dashed lines and KS2-challenged 
animals are represented by solid lines. 
Animal ID Isolate Time to initiation of anemia (dpi) PCV nadir (%) Time to PCV nadir (dpi) Treatment Intervention?
7379 KS1 27 15 34 Yes
7362 KS1 27 17 35 Yes
7096 KS1 27 19 35 Yes
7155 KS1 27 23 39 Yes*
7338 KS2 36 24 38 Yes*
7311 KS2 29 18 38 Yes
503 KS2 27 18 36 Yes
7151 KS2 31 14 38 Yes
Assessment of A. marginale  KS1 and KS2 isolate virulence
Table 2.3 – Anaplasma marginale virulence. Isolate virulence assessed using individual animal 
packed cell volume (PCV) values. (*treated with OTC despite not reaching experiment-
mandated treatment requirements.) 
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erythrocytes were evaluated as an additional measure of A. marginale infection but was not 
statistically assessed. In KS1- and KS2-challenged animals, all cows were qPCR positive for A. 
marginale by 14 dpi. From the earliest point of qPCR detection, KS2 maintained approximately 
1-log greater bacterial levels in cows compared with KS1. The slope of ascending bacteremia 
was significantly greater for KS2 (1.27×107 ±4.23×106) compared to KS1 (7.81×104 ±2.29×104; 
F=5.179, DFn = 1, DFd = 25, P 0.0317). Bacteremia levels were greater in KS2-challenged 
animals compared to KS1-challenged animals. Although the time to reach peak was longer for 
KS2-challenged animals (mean = 35, SD ±1.5 dpi; median = 36 dpi) compared with KS1-
challenged animals (mean = 29, SD ±1.9 dpi; median = 28 dpi), KS2-challenged animals reached 
significantly greater peak bacteremia (mean = 9.46×108, SD ± 7.05×108 bacteria/mL blood) than 
KS1-challenged animals (mean = 3.43×106, SD ± 1.91×106 bacteria/mL blood).   
 
Figure 2.2 – Anaplasma marginale-challenged cow bacteremia. Change in bacteremia over 
time calculated using polymerase chain reaction (PCR) where KS1-challenged animals are 
represented by dashed lines and KS2-challenged animals are represented by solid lines. 
42 
 
 
The secondary method used to monitor infection kinetics in A. marginale-challenged 
animals was PPE (Table 2.5). PPE values greater than 1% were observed for all KS1-challenged 
animals by 27 dpi and PPE values greater than 1% were observed for all KS2-challenged animals 
by 31 dpi. Peak PPE values were similar between KS1-challenged (mean = 23.5%, SD ±12.6%, 
range = 13.1 to 40.3%) and KS2-challenged (mean = 28.6%, SD ±13.2%, range = 15.7 to 43.4%) 
animals. Time to reach peak PPE value was also similar between KS1- (mean = 34.5, SD ±0.6 
dpi) and KS2-challenged (mean = 34.8, SD ±1.5 dpi) animals.  
Table 2.4 – Isolate KS1 and KS2 bacteremia. Infection kinetics as evaluated by individual 
animal and isolate average bacteremia values. 
Table 2.5 – Isolate KS1 and KS2 PPE. Infection kinetics as evaluated by individual animal 
and isolate average percent parasitized erythrocyte (PPE) values. 
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Genotype analysis of A. marginale isolates 
To confirm that cows challenged with KS1 and KS2 stabilates maintained the same 
Msp1a genotypes identified in the original donor animals (cow 1-0307 and cow 1-1018, 
respectively), the variable region of Msp1a was amplified, cloned, and sequence from each KS1- 
and KS2-challenged cow. The Msp1a genotypes identified from KS1- and KS2-challenged cows 
were consistent with the genotypes identified from the original donor cow and the 
splenectomized calf used to prepare the respective stabilates (Table 2.1). Animals challenged 
with KS1 contained a single Msp1a genotype (B B), whereas KS2-challenged animals contained 
multiple Msp1a genotypes in the ‘(K1) Dx E’ family.  
 Discussion 
Tetracycline antimicrobials have been used intensively in cattle production for the past 
half century to increase growth and as therapeutics. The FDA restricted use of medically 
important antimicrobials, such as tetracyclines, to therapeutic indications only in 2017. In 
addition, a Veterinary Feed Directive was required for any in-feed administration of a legally 
indicated, medically important antimicrobial (FDA: 21 CFR 558.6).  
Anaplasmosis is the major tick-transmitted disease of cattle in the U.S., endemic to all 
major cattle producing states. Antimicrobials are the primary means used by cattle producers to 
manage anaplasmosis in infected herds. Currently, only tetracyclines have legal use indications 
for anaplasmosis management. Reports on increasing anaplasmosis incidence in major cattle-
producing states and anecdotal reports of management difficulties have increased awareness of 
this economically costly cattle disease.  
Multiple strains of A. marginale are known to exist in the U.S. and previous reports have 
demonstrated that antimicrobial susceptibility can differ between strains. Whether intensive 
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tetracycline use in cattle production is actively selecting for more antimicrobial-tolerant A. 
marginale strains or actively driving diversification of A. marginale toward strains less 
susceptible to tetracycline antimicrobials is unclear. To address questions on the evolution of A. 
marginale antimicrobial susceptibility requires well-characterized contemporary A. marginale 
strains. Historic or laboratory A. marginale strains, not under similar sustained selective 
pressures as contemporary field-strains, may be of limited value in reflecting the susceptibility of 
contemporary A. marginale strains.  
In our experiment, two A. marginale field-isolates were isolated, propagated, and their 
virulence and infection kinetics characterized in adult beef cows. Virulence was assessed by 
monitoring the progress of anemia and temperature and by monitoring other overt clinical signs 
of disease (e.g., tachypnea, depression, anorexia).  Both isolates caused a similar reduction in 
hematocrit but time to PCV nadir was significantly longer for KS2-challenged animals. In each 
group, three of the four challenged-animals reached experiment-mandated parameters requiring 
treatment intervention. Infection kinetics of the isolates were assessed by evaluating bacteremia 
and the propagation tendencies. Both isolates developed detectable bacteremia by 14 dpi and 
KS2 maintained at least ~1 log higher bacteremia than KS1 from that point forward. Though 
KS2-challenged animals took longer to reach peak bacteremia, they reached a significantly 
greater bacterial load. The percentage of parasitized erythrocytes was measured as a secondary 
method of disease assessment but was not statistically analyzed. PPE values followed a similar 
trend as PCV values with PPE values for KS2-challenged animals above 1% being detected 
about 4 days later than KS1-challenged animals. Peak PPE values and time to reach peak PPE 
were numerically similar between animal groups.  
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The virulence of KS1 and KS2 A. marginale isolates was described by assessing the 
severity of clinical disease in challenged animals. As anemia is the hallmark of clinical 
anaplasmosis, virulence was described by monitoring the PCV of challenged animals for the 
onset of anemia. Other clinical symptoms occurred subsequent to the onset of anemia, so 
evaluating PCV nadir and time to PCV nadir were valuable also for documenting clinical 
disease. Rectal temperature, tachypnea, depression, and anorexia, all symptoms of clinical 
anaplasmosis, were monitored as virulence-related clinical parameters. These are symptoms that 
would be easily recognized by producers; however, none of the KS1- or KS2-challenged cows 
displayed overt outward signs of clinical disease. Lack of easily observable signs of clinical 
anaplasmosis is one of the major barriers to identification of animals experiencing acute 
anaplasmosis in time to intervene before death.  
Incubation periods of 29 and 33 dpi for isolates KS1 and KS2, respectively, were similar 
to those of other A. marginale strains, with the average incubation period being ~28 days (Kocan 
et al., 2003). Mean hematocrit reductions of 49.7 and 50.6% for KS1- and KS2-challenged 
animals, respectively, were also similar to previously published data which indicated that 
animals experienced a 40 to 50% reduction in red blood cells (Jones and Brock, 1966). As our 
experiment was conducted, virulence intensity was not found to differ between KS1 and KS2 
isolates, but it was unknown if either isolate would have been more likely to result in death as 
animals that reached the experiment-defined PCV intervention level were rescue-treated.  
Infection kinetics focus more on the characteristics of pathogen propagation than on 
animal symptoms. By utilizing qPCR and stained blood smears we were able to quantify and 
monitor the pathogen itself. Peak PPE calculations for KS1- and KS2-challenged animals, 23.5 
and 28.6% respectively, fell into the previously documented range of 10 to 90% parasitized 
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erythrocytes (Aubry and Geale, 2011). Although PPE determination was based upon visual 
recognition of the pathogen in red blood cells, this diagnostic was not the most accurate or 
effective in estimating bacteremia because the number of A. marginale in a single red blood cell 
can range as the colony expands (Kocan et al., 2003). Another limitation of monitoring 
anaplasmosis by blood smear is that infected red blood cells are only detectable for a few days 
around the peak of clinical disease. Molecular methods of detection such as qPCR allow for 
more accurate quantification of bacteremia and better understanding of infection kinetics. 
Animals challenged with KS1 and KS2 reached distinctly different peaks in bacteremia, but both 
fell within the ranges reported by other researchers (Palmer et al., 1999). 
 Differences in antimicrobial susceptibility have been documented between historical 
strains that have not been exposed to the same selection pressures as contemporary strains 
(Coetzee et al., 2006a,b). Considering the intensive and frequent exposure of some A. marginale 
contemporary strains to tetracyclines, it seems possible that these strains could have become 
resistant over time. With the potential that strains are becoming more resistant to tetracycline 
antimicrobials, it is important that A. marginale contemporary strains are considered when 
evaluating or re-evaluating antimicrobial efficacy.  
In summary, we isolated and characterized the virulence and infection kinetics of two A. 
marginale isolates from different Msp1a genotype families that had not been previously 
characterized. Observed PCV values indicated that virulence intensity did not differ between 
isolates; however, the time to reach PCV nadir differed between isolates. Infection kinetics were 
observed to be different among isolates as KS2-challenged animals developed bacteremia levels   
2-log greater than those developed by KS1-challenged animals. These results confirmed the 
understanding that strains with different Msp1a genotypes can differ in important disease 
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phenotypes related to development of disease and infection kinetics. Antimicrobial efficacy 
experiments against strains of A. marginale have historically been performed using laboratory 
strains that have not been under the same selection pressures as contemporary strains. To 
reassess other important A. marginale strain phenotypes, such as antimicrobial susceptibility, it is 
important to use well-characterized contemporary strains to see how these important phenotypes 
may have changed following extensive selection pressure. This experiment serves to identify and 
characterize contemporary strains to be used in future research designed to evaluate or re-
evaluate the efficacy of approved antimicrobial treatment regimens. 
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